Eisbach Bio
Phase 2A majority of cancers can be targeted by disrupting the machines that are vital to the dynamic reorganization of the tumor genome.
Founded
2019
Focus
Small Molecules
About
A majority of cancers can be targeted by disrupting the machines that are vital to the dynamic reorganization of the tumor genome.
Funding History
2Total raised: $48M
Series A$48MAndera PartnersOct 15, 2021
SeedUndisclosedUndisclosedJun 15, 2019
Company Info
TypePrivate
Founded2019
LocationMunich, Germany
StagePhase 2
Contact
SIMILAR COMPANIES
300Microns
Pre-clinical · Munich
BetaSense
Pre-clinical · Berlin
AB Diagnostic Systems
Pre-clinical · Jena
bbi-biotech
Pre-clinical · Berlin
Mireca Medicines
Pre-clinical · Munich
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile